Search research articles
Contact Us
Filters
Showing results (141-150 of 350) with videos related to
Page
of 35
Sort By:
The Oncologist
|
May 30, 2019
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
Ari Joseph Rosenberg, Alfred Rademaker, Howard S Hochster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2023
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Oncology
|
October 18, 2017
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)
Jordan D Berlin, Yang Feng, Paul Catalano, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2016
Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy
Sherif R Z Abdel-Misih, Lai Wei, Al B Benson, et al.
Investigational New Drugs
|
October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
November 12, 2024
Yttrium-90 Radiation Segmentectomy for Treatment of Neuroendocrine Liver Metastases
Andrew C Gordon, Rohan Savoor, Sheetal M Kircher, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
July 5, 2017
Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver
Yu-Kai Su, Rosewell V Mackey, Ahsun Riaz, et al.
Annals of Internal Medicine
|
October 22, 2003
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
Jeffrey A Meyerhardt, Paul J Catalano, Deborah Schrag, et al.
Clinical Colorectal Cancer
|
September 5, 2015
Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies
Sangeetha M Reddy, Maxwell T Vergo, Judith A Paice, et al.
Investigational New Drugs
|
September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Laura W Goff, Al B Benson, Patricia M LoRusso, et al.
Page
of 35
Search research articles
Search
Showing results (141-150 of 350) with videos related to
Sort By:
Page
of 35
The Oncologist
|
May 30, 2019
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
Ari Joseph Rosenberg, Alfred Rademaker, Howard S Hochster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2023
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Oncology
|
October 18, 2017
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)
Jordan D Berlin, Yang Feng, Paul Catalano, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2016
Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy
Sherif R Z Abdel-Misih, Lai Wei, Al B Benson, et al.
Investigational New Drugs
|
October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
November 12, 2024
Yttrium-90 Radiation Segmentectomy for Treatment of Neuroendocrine Liver Metastases
Andrew C Gordon, Rohan Savoor, Sheetal M Kircher, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
July 5, 2017
Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver
Yu-Kai Su, Rosewell V Mackey, Ahsun Riaz, et al.
Annals of Internal Medicine
|
October 22, 2003
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
Jeffrey A Meyerhardt, Paul J Catalano, Deborah Schrag, et al.
Clinical Colorectal Cancer
|
September 5, 2015
Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies
Sangeetha M Reddy, Maxwell T Vergo, Judith A Paice, et al.
Investigational New Drugs
|
September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Laura W Goff, Al B Benson, Patricia M LoRusso, et al.
Page
of 35